Global Cosmetic Products Market Will Reach USD 863 Billion by 2024: Zion Market Research
/
Date23 Jun 2018
New York, NY, June 22, 2018 (GLOBE NEWSWIRE) — Zion Market Research has published a new report titled “Cosmetic Products Market by Product (Skincare products,... Read More →
Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial
/
Date23 Jun 2018
Orlando, US, 23 June 2018 - Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo... Read More →
Griffin Institutional Access® Real Estate Fund Announces Second Quarter Distribution
/
Date23 Jun 2018
EL SEGUNDO, Calif., June 22, 2018 (GLOBE NEWSWIRE) — Griffin Capital Company, LLC announced today on behalf of Griffin Institutional Access Real Estate Fund (NASDAQ:GIREX)... Read More →
Results of Operations for the Year Ended December 31, 2017 – American Overseas Group Limited Announces Net Loss Of $10.6 Million and Operating Loss of $20.8 Million For The Year Ended December 31, 2017
/
Date23 Jun 2018
HAMILTON, Bermuda, June 22, 2018 (GLOBE NEWSWIRE) — American Overseas Group Limited (BSX:AOREF.BH) (Pink Sheets:AOREF.PK) (“AOG” or the “Company”) today reported consolidated net loss available... Read More →
Braille Energy Systems Inc. Announces Closing of Reverse Takeover Transaction
/
Date23 Jun 2018
OTTAWA, June 22, 2018 (GLOBE NEWSWIRE) — Braille Energy Systems Inc. (formerly Mincom Capital Inc.) (TSX-VENTURE:MOI) (the “Company” or “BESI”), is pleased to announce, effective June... Read More →
CORRECTION: Audited financial report of year 2017 of AS “Rīgas kuģu būvētava”
/
Date23 Jun 2018
Correction: in the audited financial report of year 2017 in section Balance Sheet/Equity, Provisions and Liabilities in English incorrectly specified amount of a total equity... Read More →
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
/
Date23 Jun 2018
Trial met all primary objectives, demonstrated efficacy and safety and established minimally effective dose of 0.9 mg for ZGN-1061 Patient dosing recently initiated for the... Read More →
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand
/
Date23 Jun 2018
CHICAGO, June 23, 2018 (GLOBE NEWSWIRE) — BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today... Read More →